Hyperlipidemia-induced hepatic and small intestine ER stress and decreased paraoxonase 1 expression and activity is associated with HDL dysfunction in Syrian hamsters

Molecular Nutrition and Food Research

Volumn 59, Issue 11, 2015, Pages 2293-2302

  Stancu, Camelia S ^a   Carnuta, Mihaela G ^a   Sanda, Gabriela M ^a   Toma, Laura ^a   Deleanu, Mariana ^a,b   Niculescu, Loredan S ^a   Sasson, Shlomo ^c   Simionescu, Maya ^a   Sima, Anca V ^a  

^a INSTITUTE OF CELLULAR BIOLOGY AND PATHOLOGY NICOLAE SIMIONESCU   (Romania)

^b UNIVERSITY OF AGRONOMIC SCIENCES AND VETERINARY MEDICINE OF BUCHAREST   (Romania)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

ER stress; Hyperlipidemia; Liver; Paraoxonase 1; Small intestine

Indexed keywords

ARYLDIALKYLPHOSPHATASE; GLUCOSE TRANSPORTER 2; HIGH DENSITY LIPOPROTEIN;

ANIMAL; CARDIAC MUSCLE; ENDOPLASMIC RETICULUM STRESS; GENETICS; HAMSTER; HYPERLIPIDEMIA; LIPID DIET; LIVER; MALE; MESOCRICETUS; METABOLISM; PHYSIOLOGY; SMALL INTESTINE;

ANIMALS; ARYLDIALKYLPHOSPHATASE; CRICETINAE; DIET, HIGH-FAT; ENDOPLASMIC RETICULUM STRESS; GLUCOSE TRANSPORTER TYPE 2; HYPERLIPIDEMIAS; INTESTINE, SMALL; LIPOPROTEINS, HDL; LIVER; MALE; MESOCRICETUS; MYOCARDIUM;

EID: 84941711251     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201500422     Document Type: Article

References (37)

1. Mascarenhas-Melo, F., Sereno, J., Teixeira-Lemos, E., Marado, D. et al., Implication of low HDL-c levels in patients with average LDL-c levels: a focus on oxidized LDL, large HDL subpopulation, and adiponectin. Mediators Inflamm. 2013, 2013, 612038.
2. Toth, P. P., Barter, P. J., Rosenson, R. S., Boden, W. E. et al., High-density lipoproteins: a consensus statement from the National Lipid Association. J. Clin. Lipidol. 2013, 7, 484-525.
3. Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M. et al., Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 2007, 357, 2109-2122.
4. Boden, W. E., Probstfield, J. L., Anderson, T., Chaitman, B. R. et al., Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 2011, 365, 2255-2267.
5. Mooradian, A. D., Haas, M. J., Targeting high-density lipoproteins: increasing de novo production versus decreasing clearance. Drugs 2015, 75, 713-722.
6. Pirillo, A., Tibolla, G., Norata, G. D., Catapano, A. L., HDL: to treat or not to treat? Curr. Atheroscler. Rep. 2014, 16, 429.
7. Hovingh, G. K., Rader, D. J., Hegele, R. A., HDL re-examined. Curr. Opin. Lipidol. 2015, 26, 127-132.
8. Litvinov, D., Mahini, H., Garelnabi, M., Antioxidant and anti-inflammatory role of paraoxonase 1: implication in arteriosclerosis diseases. N. Am. J. Med. Sci. 2012, 4, 523-532.
9. Shao, B., Site-specific oxidation of apolipoprotein A-I impairs cholesterol export by ABCA1, a key cardioprotective function of HDL. Biochim. Biophys. Acta 2012, 1821, 490-501.
10. Toth, P. P., Davidson, M. H., High-density lipoproteins: marker of cardiovascular risk and therapeutic target. J. Clin. Lipidol. 2010, 4, 359-364.
11. Stancu, C. S., Sanda, G. M., Deleanu, M., Sima, A. V., Probiotics determine hypolipidemic and antioxidant effects in hyperlipidemic hamsters. Mol. Nutr. Food Res. 2014, 58, 559-568.
12. Aviram, M., Vaya, J., Paraoxonase 1 activities, regulation, and interactions with atherosclerotic lesion. Curr. Opin. Lipidol. 2013, 24, 339-344.
13. Shamir, R., Hartman, C., Karry, R., Pavlotzky, E. et al., Paraoxonases (PONs) 1, 2, and 3 are expressed in human and mouse gastrointestinal tract and in Caco-2 cell line: selective secretion of PON1 and PON2. Free Radic. Biol. Med. 2005, 39, 336-344.
14. Mackness, B., Beltran-Debon, R., Aragones, G., Joven, J. et al., Human tissue distribution of paraoxonases 1 and 2 mRNA. IUBMB Life 2010, 62, 480-482.
15. Haraguchi, Y., Toh, R., Hasokawa, M., Nakajima, H. et al., Serum myeloperoxidase/paraoxonase 1 ratio as potential indicator of dysfunctional high-density lipoprotein and risk stratification in coronary artery disease. Atherosclerosis 2014, 234, 288-294.
16. Kostapanos, M. S., Elisaf, M. S., High density lipoproteins and type 2 diabetes: emerging concepts in their relationship. World J. Exp. Med. 2014, 4, 1-6.
17. Gouedard, C., Koum-Besson, N., Barouki, R., Morel, Y., Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins. Mol. Pharmacol. 2003, 63, 945-956.
18. Khateeb, J., Gantman, A., Kreitenberg, A. J., Aviram, M. et al., Paraoxonase 1 (PON1) expression in hepatocytes is upregulated by pomegranate polyphenols: a role for PPAR-gamma pathway. Atherosclerosis 2010, 208, 119-125.
19. Hummasti, S., Hotamisligil, G. S., Endoplasmic reticulum stress and inflammation in obesity and diabetes. Circ. Res. 2010, 107, 579-591.
20. Musso, G., Gambino, R., Cassader, M., Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. Prog. Lipid. Res. 2013, 52, 175-191.
21. Panchal, S. K., Brown, L., Rodent models for metabolic syndrome research. J. Biomed. Biotechnol. 2011, 2011, 351982.
22. Sullivan, M. P., Cerda, J. J., Robbins, F. L., Burgin, C. W. et al., The gerbil, hamster, and guinea pig as rodent models for hyperlipidemia. Lab. Anim. Sci. 1993, 43, 575-578.
23. Mineo, C., Shaul, P. W., PON-dering differences in HDL function in coronary artery disease. J. Clin. Invest. 2011, 121, 2545-2548.
24. Charles-Schoeman, C., Lee, Y. Y., Grijalva, V., Amjadi, S. et al., Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis. Ann. Rheum. Dis. 2012, 71, 1157-1162.
25. Hussain, M. M., Intestinal lipid absorption and lipoprotein formation. Curr. Opin. Lipidol. 2014, 25, 200-206.
26. Volmer, R., van der Ploeg, K., Ron, D., Membrane lipid saturation activates endoplasmic reticulum unfolded protein response transducers through their transmembrane domains. Proc. Natl. Acad. Sci. USA 2013, 110, 4628-4633.
27. Ducheix, S., Montagner, A., Theodorou, V., Ferrier, L. et al., The liver X receptor: a master regulator of the gut-liver axis and a target for nonalcoholic fatty liver disease. Biochem. Pharmacol. 2013, 86, 96-105.
28. Turfaner, N., Uzun, H., Balci, H., Ercan, M. A. et al., Ezetimibe therapy and its influence on oxidative stress and fibrinolytic activity. South Med. J. 2010, 103, 428-433.
29. Boesch-Saadatmandi, C., Niering, J., Minihane, A. M., Wiswedel, I. et al., Impact of apolipoprotein E genotype and dietary quercetin on paraoxonase 1 status in apoE3 and apoE4 transgenic mice. Atherosclerosis 2010, 211, 110-113.
30. Khateeb, J., Kiyan, Y., Aviram, M., Tkachuk, S. et al., Urokinase-type plasminogen activator downregulates paraoxonase 1 expression in hepatocytes by stimulating peroxisome proliferator-activated receptor-gamma nuclear export. Arterioscler. Thromb. Vasc. Biol. 2012, 32, 449-458.
31. Gutierrez, A., Ratliff, E. P., Andres, A. M., Huang, X. et al., Bile acids decrease hepatic paraoxonase 1 expression and plasma high-density lipoprotein levels via FXR-mediated signaling of FGFR4. Arterioscler. Thromb. Vasc. Biol. 2006, 26, 301-306.
32. Cheng, C. C., Hsueh, C. M., Liang, K. W., Ting, C. T. et al., Role of JNK and c-Jun signaling pathway in regulation of human serum paraoxonase 1 gene transcription by berberine in human HepG2 cells. Eur. J. Pharmacol. 2011, 650, 519-525.
33. Shearn, C. T., Fritz, K. S., Reigan, P., Petersen, D. R., Modification of Akt2 by 4-hydroxynonenal inhibits insulin-dependent Akt signaling in HepG2 cells. Biochemistry 2011, 50, 3984-3996.
34. Cohen, G., Riahi, Y., Sunda, V., Deplano, S. et al., Signaling properties of 4-hydroxyalkenals formed by lipid peroxidation in diabetes. Free Radic. Biol. Med. 2013, 65, 978-987.
35. Koren-Gluzer, M., Aviram, M., Hayek, T., Paraoxonase1 (PON1) reduces insulin resistance in mice fed a high-fat diet, and promotes GLUT4 overexpression in myocytes, via the IRS-1/Akt pathway. Atherosclerosis 2013, 229, 71-78.
36. Karim, S., Adams, D. H., Lalor, P. F., Hepatic expression and cellular distribution of the glucose transporter family. World J. Gastroenterol. 2012, 18, 6771-6781.
37. Tobin, V., Le Gall, M., Fioramonti, X., Stolarczyk, E. et al., Insulin internalizes GLUT2 in the enterocytes of healthy but not insulin-resistant mice. Diabetes 2008, 57, 555-562.